Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06879067 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
A Phase 1 study, sponsored by Tiziana Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06879067 is a Phase 1 study that has completed, run by Tiziana Life Sciences. The registered enrollment target is 27 participants.
The verdict
NCT06879067, a Phase 1 study, has completed, sponsored by Tiziana Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
Interventions
- DRUG Placebo
- DRUG Foralumab Nasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06879067
The ClinicalTrials.gov registry entry for NCT06879067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tiziana Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06879067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06879067 about?
NCT06879067 is a clinical study titled "Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers". The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
What is the current status of trial NCT06879067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-11-12. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT06879067?
The interventions under investigation include: Placebo (DRUG), Foralumab Nasal (DRUG).
Who is sponsoring clinical trial NCT06879067?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.